Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
New analysis suggests specific chemo schedules may improve outcomes for early breast cancer patients
This network meta-analysis evaluated Phase II and Phase III trials involving 17,187 women with early-stage breast cancer receiving adjuvant…
A new analysis of 17,187 women with early breast cancer suggests specific chemo schedules may improve outcomes and reduce side effects.
Atezolizumab plus chemotherapy improved progression-free survival and patient-reported quality of life in metastatic triple-negative breast cancer
Adding atezolizumab to chemotherapy improved quality of life and survival in some patients with metastatic triple-negative breast cancer
This randomized trial evaluated adding atezolizumab to anthracycline-based chemotherapy versus chemotherapy plus placebo in patients with me…
Adding atezolizumab to chemotherapy improved quality of life, emotional functioning, and pain for patients with metastatic triple-negative b…
Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer
Combination therapy improved response rates in a small study of triple-negative breast cancer patients
This retrospective cohort study evaluated 61 patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy at a single ce…
Adding the immunotherapy drug sintilimab to standard chemotherapy boosted response rates and slowed tumor growth in triple-negative breast c…
Pyroptosis-related gene signature predicts prognosis in triple-negative breast cancer patients
Can a gene signature predict survival for triple-negative breast cancer patients?
This observational cohort study analyzed data from TCGA and GEO databases, validated in an independent GEO cohort and 48 clinical samples, t…
A genetic warning system in triple-negative breast cancer tumors can predict which patients face a higher risk of the cancer returning.
Population study links PALB2 variants to increased cancer risk and mortality in two large cohorts
Large study finds PALB2 gene variant linked to higher cancer risk and mortality
A case-control study of over 636,000 adults from UK Biobank and Geisinger MyCode cohorts found heterozygous PALB2 pathogenic/likely pathogen…
A common gene variant called PALB2 is linked to higher odds of breast, pancreatic, and other cancers plus reduced survival compared to peopl…
Phase Ib trial: Mam-A DNA vaccine plus endocrine therapy induces T cells in ER+ breast cancer
Can a breast cancer vaccine help the immune system target tumors?
A phase Ib clinical trial in 21 patients with estrogen receptor-positive breast cancer prior to surgery found that adding Mammaglobin-A DNA …
A breast cancer vaccine triggered specific immune cells to attack tumors in early trial patients, showing promising biological activity befo…
PSMA PET/CT shows uptake in half of metastatic triple-negative breast cancer patients
Can a prostate cancer scan help treat aggressive breast cancer?
A prospective single-center study of 20 patients with progressive mTNBC found that 50% showed visual PSMA positivity on [Ga]Ga-PSMA-11 PET/C…
A prostate cancer scan found PSMA targets in half of aggressive breast cancer tumors, suggesting a new therapy option for patients when stan…
DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT
Breath-hold technique reduces radiation dose to heart during breast cancer treatment
A meta-analysis of 11 studies in left-sided breast cancer patients treated with VMAT found deep inspiration breath hold (DIBH) reduced mean …
Holding a deep breath during radiation therapy consistently lowers the dose to the heart, lungs, and other organs for left-sided breast canc…
Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer
Can a single radiation dose protect women after breast cancer surgery?
A prospective single-institution phase 2 trial of 148 patients with early-stage breast cancer after breast-conserving surgery found single-f…
A single radiation dose for breast cancer recovery showed low recurrence and mild side effects in early results from a new treatment approac…
Adjusted Breast Cancer Index model identifies minimal-risk groups in premenopausal HR+ node-negative breast cancer
Study refines tool to identify low-risk breast cancer in younger women
This RCT analysis of 2025 premenopausal patients with HR+ node-negative breast cancer from SOFT/TEXT trials evaluated an adjusted BCI model …
A new tool identifies younger women with low-risk breast cancer who face only a 2% chance of the disease spreading within 10 years.
Research across Cancer
Related studies from across the Cancer family.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Lymphovenous anastomosis improves quality of life in breast cancer-related lymphedema
Lymphedema surgery improves quality of life in breast cancer survivors
This meta-analysis of observational studies found that therapeutic lymphovenous anastomosis (LVA) significantly improves quality of life in …
A new analysis finds that lymphovenous anastomosis significantly boosts quality of life for breast cancer survivors with lymphedema, especia…
Weight reduction ranked highest for limb volume, while VR-based training ranked highest for pain in breast cancer-related lymphedema
Weight loss and virtual reality rank highest for breast cancer swelling and pain relief
This network meta-analysis of 754 patients evaluated non-pharmacological therapies for breast cancer-related lymphedema. Weight reduction ra…
Weight loss and virtual reality training ranked best for reducing arm swelling and pain in breast cancer patients, though other therapies al…
Healthcare professionals need updated guidance on managing breast cancer-related lymphedema effectively today
Review updates care for breast cancer-related lymphedema
This narrative review aims to apprise healthcare professionals with the latest understanding of optimal care and counseling patients regardi…
A new review summarizes the latest understanding of breast cancer-related lymphedema to help healthcare professionals counsel patients.
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Protocol for randomized controlled trial of TEAS pretreatment for breast cancer-related lymphedema
New electrical therapy may stop breast cancer swelling before surgery starts
This document outlines a randomized controlled trial protocol evaluating transcutaneous electrical acupoint stimulation pretreatment in brea…
A new electrical therapy might stop arm swelling before breast cancer surgery begins
Questions about Hormone Receptor-Positive Breast Cancer
Is trastuzumab deruxtecan better than chemotherapy for HR-positive breast cancer?
Yes, trastuzumab deruxtecan improves progression-free survival compared to chemotherapy in HR-positive, HER2-low breast cancer, but overall survival data are not yet mature.
Full answer →Does datopotamab deruxtecan improve survival for Hormone Receptor-Positive Breast Cancer?
Datopotamab deruxtecan did not improve overall survival compared to chemotherapy in metastatic HR-positive breast cancer, despite improving progression-free survival.
Full answer →